ClinicalTrials.gg

Program

sparsentan

Also written as “Sparsentan”, “PS433540” and “RE-021 (Sparsentan)”.

Its studies are mostly in Glomerulosclerosis, Focal Segmental · Glomerulonephritis, IGA · Hypertension · Proteinuria, led by 2 companies.

Furthest: phase 4, since Oct 9, 20259 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Travere Therapeutics72 open or runningphase 4since Oct 9, 2025Jun 4, 2012Mar 2027phase 4 · NCT07219121
Ligand Pharmaceuticals20 open or runningphase 2since Aug 29, 2007Aug 29, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2007First study: phase 2 study in HypertensionNew to Ligand PharmaceuticalsLigand Pharmaceuticals · NCT00522925 · 280 enrolled · United States
  2. Mar 6, 2008Phase 2 study in HypertensionLigand Pharmaceuticals · NCT00635232 · 261 enrolled · United States
  3. Jun 4, 2012Travere Therapeutics's first study: phase 2 study in Glomerulosclerosis, Focal SegmentalNew to Travere TherapeuticsTravere Therapeutics · NCT01613118 · 109 enrolled · United States, Czechia, Italy
  4. Apr 3, 2018Phase 3 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT03493685 · 371 enrolled · United States, Argentina, Australia and more
  5. Nov 27, 2018Phase 3 study in Glomerulonephritis, IGATravere Therapeutics · NCT03762850 · 406 enrolled · United States, Australia, Belgium and more
  6. Jul 29, 2021Phase 2 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT05003986 · 67 planned · United States, Germany, Italy and more
  7. Aug 23, 2022Phase 1 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT05562362 · 47 enrolled · United Kingdom
  8. May 3, 2023Phase 2 study in Glomerulonephritis, IGATravere Therapeutics · NCT05856760 · 48 enrolled · United States, Hong Kong
  9. Oct 9, 2025Phase 4 study in ProteinuriaTravere Therapeutics · NCT07219121 · 20 enrolled · United States

Ahead

  1. Mar 2027Primary completion: phase 4 study in ProteinuriaTravere Therapeutics · NCT07219121
  2. Mar 12, 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalTravere Therapeutics · NCT05003986

TargetBeta

AGTR1 →EDNRA →read by rule
“Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07219121Proteinuria · United States4Active, not recruitingTravere TherapeuticsMar 202720
NCT05856760Glomerulonephritis, IGA · United States, Hong Kong2CompletedTravere TherapeuticsOct 14, 202448
NCT05562362Glomerulosclerosis, Focal Segmental · United Kingdom1CompletedTravere TherapeuticsNov 12, 202047
NCT05003986Glomerulosclerosis, Focal Segmental · United States, Germany, Italy and more2RecruitingTravere TherapeuticsMar 12, 202767
NCT03762850Glomerulonephritis, IGA · United States, Australia, Belgium and more3CompletedTravere TherapeuticsAug 7, 2023406
NCT03493685Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more3CompletedTravere TherapeuticsMar 20, 2023371
NCT01613118Glomerulosclerosis, Focal Segmental · United States, Czechia, Italy2CompletedTravere TherapeuticsJun 2016109
NCT00635232Hypertension · United States2CompletedLigand PharmaceuticalsNov 2008261
NCT00522925Hypertension · United States2CompletedLigand PharmaceuticalsApr 2008280

How it is read

Names in the registry

  • “Sparsentan”, 5 entries
  • “PS433540”, 5 entries
  • “sparsentan”, 2 entries
  • “RE-021 (Sparsentan)”, 1 entry
  • “RE-021, sparsentan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.